“Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s612. doi:10.25251/m9gw3y80.